Targeting a specific signaling pathway to treat high-risk osteosarcoma
Identifying and overcoming mechanisms of resistance to effectively target the TBL1/β-catenin signaling axis for high-risk osteosarcoma
This study is looking at a new way to help people with high-risk osteosarcoma, a tough type of bone cancer, by testing a special medicine called Tegavivint that aims to stop the cancer from growing and spreading while keeping healthy cells safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10943147 on NIH RePORTER |
What this research studies
This research focuses on understanding and overcoming the mechanisms that make high-risk osteosarcoma resistant to treatment. It investigates the role of the TBL1/β-catenin signaling axis, which is involved in tumor growth and spread. The study utilizes a novel small molecule inhibitor called Tegavivint, which aims to disrupt the harmful interactions within this signaling pathway without affecting normal cell functions. By doing so, the research seeks to improve treatment outcomes for patients with this aggressive form of bone cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are pediatric patients diagnosed with high-risk osteosarcoma, particularly those who have relapsed or are refractory to standard treatments.
Not a fit: Patients with low-risk osteosarcoma or those whose cancer has not progressed may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for high-risk osteosarcoma, potentially improving survival rates and quality of life for affected patients.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting the Wnt signaling pathway in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Yustein, Jason — Emory University
- Study coordinator: Yustein, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.